Quest Diagnostics (DGX) Q3 2025 10-Q Quarterly Report
Quest Diagnostics (DGX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 21, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Quest Diagnostics Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $2.82B for Q3 2025, up 13.1% YoY from $2.49B; DIS revenues $2.76B, up 13.5% YoY from $2.43B
- • Operating margin 13.7% vs 13.3% YoY; Operating income $386M, up 16.8% YoY from $330M
- • Best segment DIS: revenue up 13.5% to $2.76B with 12.5% volume growth; Worst segment DS revenues down 1.0% to $61M
- • Operating cash flow $563M, up $207M YoY; Capital expenditures $144M, up $38M YoY; cash and equivalents $432M vs $549M year-end 2024
- • Management notes potential 50-60 bps revenue reduction by 2028 from new healthcare legislation; ongoing Invigorate cost savings program targeting 3% annual savings
Risk Factors
- • No new or changed risk factors since 2024 10-K according to 10-Q filing
- • Continued exposure to regulatory risks from healthcare compliance and reimbursement policy changes
- • Operational risks from dependence on laboratory testing volume and reimbursement rates remain significant
- • Competitive risks from evolving healthcare market and innovation pressure persist
- • Financial risks related to liquidity and debt maturity remain stable with no material updates
Quest Diagnostics Q3 2025 Quarterly FinancialsXBRL
Revenue
$2.8B
▲ +13.2% YoY▲ +2.0% QoQ
Net Income
$245M
▲ +8.4% YoY▼ -13.1% QoQ
Net Margin
8.7%
▼ -38bp YoY▼ -151bp QoQ
Source: XBRL data from Quest Diagnostics Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Quest Diagnostics
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.